We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
-8.23%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$13.7M
(-5.5%)
Cap. Flow
+$21.9M
Cap. Flow
% of AUM
9.32%
Top 10 Holdings %
Top 10 Hldgs %
80.18%
Holding
22
New
2
Increased
4
Reduced
4
Closed
–
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$9.51M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$6.29M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$4.99M |
| 4 |
89bio
ETNB
|
+$3.42M |
| 5 |
Cogent Biosciences
COGT
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$3.93M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$1.35M |
| 3 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$1.04M |
| 4 |
Tango Therapeutics
TNGX
|
+$498K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cogent Biosciences
COGT
$4.88B
| $31.4M | 13.34% |
3,481,042
+500,000
| +17% | +$3.41M |
2021 Q4
2 quarters
|
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $28M | 11.91% |
2,914,250
+397,330
| +16% | +$4.99M |
2021 Q4
2 quarters
|
|
3
Geron
GERN
$765M
| $23.4M | 9.94% |
15,096,342
+810,627
| +6% | +$1.15M |
2022 Q1
1 quarter
|
|
|
4
Kura Oncology
KURA
$855M
| $21.4M | 9.09% |
1,167,642
+661,219
| +131% | +$9.51M |
2022 Q1
1 quarter
|
|
5
DELISTED
Cymabay Therapeutics
CBAY
| $17.4M | 7.4% |
5,905,400
| – | – |
2021 Q4
2 quarters
|
|
6
Aclaris Therapeutics
ACRS
$498M
| $16M | 6.79% |
1,144,939
| – | – |
2021 Q4
2 quarters
|
|
7
Viridian Therapeutics
VRDN
$2.08B
| $15.2M | 6.46% |
1,314,000
| – | – |
2021 Q4
2 quarters
|
|
|
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $13.9M | 5.92% |
796,460
-85,893
| -10% | -$1.35M |
2021 Q4
2 quarters
|
|
9
Jade Biosciences
JBIO
$855M
| $13.9M | 5.91% |
25,416
| – | – |
2021 Q4
2 quarters
|
|
10
Entrada Therapeutics
TRDA
$177M
| $8.08M | 3.43% |
663,694
| – | – |
2021 Q4
2 quarters
|
|
11
DELISTED
Merus
MRUS
| $6.79M | 2.89% |
300,000
| – | – |
2021 Q4
2 quarters
|
|
12
Tyra Biosciences
TYRA
$1.29B
| $6.41M | 2.72% |
896,418
| – | – |
2021 Q4
2 quarters
|
|
|
AKUS
13
DELISTED
Akouos Inc
AKUS
| $6.33M | 2.69% |
1,350,006
| – | – |
2021 Q4
2 quarters
|
|
|
14
Tango Therapeutics
TNGX
$3.74B
| $5.31M | 2.26% |
1,172,250
-82,250
| -7% | -$498K |
2022 Q1
1 quarter
|
|
|
15
MoonLake Immunotherapeutics
MLTX
$863M
| $5.25M | 2.23% |
+1,000,000
| New | +$6.29M |
2022 Q2
0 quarters
|
|
|
16
DELISTED
Alpine Immune Sciences Inc
ALPN
| $4.92M | 2.09% |
578,260
-455,962
| -44% | -$3.93M |
2021 Q4
2 quarters
|
|
|
17
DELISTED
89bio
ETNB
| $3.65M | 1.55% |
+1,133,196
| New | +$3.42M |
2022 Q2
0 quarters
|
|
18
Zai Lab
ZLAB
$2.53B
| $3.29M | 1.4% |
95,000
| – | – |
2021 Q4
2 quarters
|
|
19
Dianthus Therapeutics
DNTH
$4.18B
| $2.55M | 1.08% |
132,758
| – | – |
2021 Q4
2 quarters
|
|
20
AnaptysBio
ANAB
$1.4B
| $1.19M | 0.5% |
58,515
| – | – |
2022 Q1
1 quarter
|
|
21
DELISTED
Elevation Oncology
ELEV
| $777K | 0.33% |
555,000
| – | – |
2021 Q4
2 quarters
|
|
|
PRDS
22
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $181K | 0.08% |
59,039
-170,061
| -74% | -$1.04M |
2022 Q1
1 quarter
|
|
Similar funds
CCMIC
TCG Crossover Management's Q2 2022 Portfolio in Review
As of Q2 2022, TCG Crossover Management held 22 positions worth $235M, down 5.5% from $249M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
TCG Crossover Management deployed $21.9M of net new capital in Q2 2022, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,000,000 shares worth $5.25M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Alpine Immune Sciences Inc, an estimated $3.93M trimmed.
- TCG Crossover Management's largest Q2 2022 buy was MoonLake Immunotherapeutics: 1,000,000 shares worth $5.25M.
- TCG Crossover Management added most to Kura Oncology in Q2 2022, an estimated $9.51M increase.
- TCG Crossover Management's biggest Q2 2022 reduction was Alpine Immune Sciences Inc, cutting an estimated $3.93M.
- TCG Crossover Management's ten largest holdings make up 80% of its $235M portfolio in Q2 2022.
- TCG Crossover Management opened 2 new positions and closed 0 in Q2 2022.
- TCG Crossover Management's portfolio value fell 5.5% quarter-over-quarter to $235M.
Based on TCG Crossover Management's 13F filing for Q2 2022, filed 15 Aug 2022.